EGFR Exon 20 Mutation clinical trials at University of California Health
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
CLN-081-101 is a Phase 1/2a, open label, multi-center study of CLN-081 in patients with NSCLC (non small cell lung cancer) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
at UC Davis